SMARCAL1是ATRX缺陷且依赖ALT的胶质瘤中的可靶向合成致死弱点
该研究基于癌症依赖图谱计划的CRISPR/Cas9筛选数据,结合患者来源细胞系与异种移植模型,发现SMARCAL1是ATRX缺陷且使用ALT的胶质瘤中的合成致死靶点。SMARCAL1缺失导致ALT表型过度激活、G2期DNA双链断裂增加及有丝分裂灾难性细胞死亡,并在颅内异种移植小鼠中延长生存期。结果支持开发SMARCAL1小分子抑制剂作为抗癌治疗。
要点
- SMARCAL1是ATRX缺陷且依赖ALT的胶质瘤中的特异性合成致死靶点。
- SMARCAL1缺失过度激活ALT表型,诱导G2期DNA双链断裂和有丝分裂灾难。
- 诱导性SMARCAL1缺失延长IDH突变星形细胞瘤颅内异种移植小鼠生存期。
核心结论
- SMARCAL1是ATRX缺陷且使用ALT的胶质瘤中的可靶向合成致死弱点。
- 靶向SMARCAL1可诱导ALT阳性胶质瘤细胞死亡并延长小鼠生存期。
研究设计与样本
- 利用癌症依赖图谱计划的CRISPR/Cas9筛选数据,结合患者来源细胞系和异种移植模型。
- 采用DNA损伤、端粒维持和端粒复制应激的分子检测定义机制。
主要发现
- SMARCAL1定位于ALT阳性胶质瘤细胞系(包括IDH突变星形细胞瘤)的ALT相关PML小体。
- 多西环素诱导的RNAi敲低SMARCAL1导致ALT表型过度激活、G2期高水平DNA双链断裂和通过有丝分裂灾难的细胞死亡。
- 在源自高级别IDH突变星形细胞瘤的颅内异种移植小鼠中,诱导性SMARCAL1敲低延长动物生存期。
临床怎么用
- SMARCAL1抑制可作为ATRX缺陷且依赖ALT的胶质瘤的潜在合成致死治疗策略。
- 支持未来开发SMARCAL1小分子抑制剂作为抗癌药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 10% of cancers achieve replicative immortality through a telomerase-independent mechanism of telomere maintenance, termed Alternative Lengthening of Telomeres (ALT). ALT is particularly prevalent in certain subtypes of malignant gliomas, such as IDH-mutant astrocytoma and pediatric glioblastoma, and frequently co-occurs with ATRX (ATRX chromatin remodeler) inactivating mutations. Although ALT is an adaptive mechanism through which cancer cells achieve proliferative immortality, the elevated levels of replication stress observed in ALT tumors constitute a potential therapeutic vulnerability. METHODS: Leveraging CRISPR/Cas9 screening data from the Cancer Dependency Mapping Project, coupled with patient-derived cell lines and xenografts, we identified SMARCAL1 as a novel synthetic lethal vulnerability in ATRX-deficient glioma models that engage ALT. Using complementary molecular assays for DNA damage, telomere maintenance, and telomeric replication stress, we define the mechanisms underlying cytotoxicity induced by SMARCAL1 depletion in ALT-positive glioma cells. RESULTS: Our data demonstrate the annealing helicase SMARCAL1 is a highly specific synthetical lethal vulnerability in cancers that use ALT. SMARCAL1 localizes to ALT-associated PML (Promyelocytic leukemia protein) bodies in ALT-positive glioma cell lines, including IDH-mutant astrocytomas. SMARCAL1 depletion, via doxycycline-induced RNAi, led to a hyperactivation of the ALT phenotype, high levels of DNA double-strand breaks in G2 phase, and cell death via mitotic catastrophe. In mice bearing intracranial xenografts derived from high-grade IDH-mutant astrocytoma, inducible SMARCAL1 depletion prolonged animal survival. CONCLUSIONS: Our findings demonstrate that the molecular processes orchestrating ALT-mediated telomere maintenance constitute a targetable synthetic lethal vulnerability that can be exploited by SMARCAL1 inhibition, thus supporting the future development of small molecule inhibitors of SMARCAL1 as anti-cancer therapeutics.
引用
- Brown A, Strickland LM, Erman EN, et al. SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres. Neuro Oncol. 2026. PMID: 41520142. doi:10.1093/neuonc/noaf300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。